Macquarie Group
SUPN icon

Macquarie Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Macquarie Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,531,537
Closed -$121M – 1429
2025
Q3 		$121M Sell
2,531,537
-230,587
-8% -$9.29M 0.14% 170
2025
Q2 		$87.1M Buy
2,762,124
+62,457
+2% +$2M 0.11% 271
2025
Q1 		$88.4M Buy
2,699,667
+70,760
+3% +$2.51M 0.11% 263
2024
Q4 		$95.1M Sell
2,628,907
-2,990
-0.1% -$105K 0.12% 246
2024
Q3 		$82.1M Sell
2,631,897
-47,899
-2% -$1.49M 0.09% 311
2024
Q2 		$71.7M Buy
2,679,796
+10,800
+0.4% +$313K 0.08% 315
2024
Q1 		$91M Sell
2,668,996
-68,720
-3% -$2.05M 0.1% 258
2023
Q4 		$79.2M Sell
2,737,716
-13,140
-0.5% -$348K 0.09% 302
2023
Q3 		$75.8M Buy
2,750,856
+247,398
+10% +$7.53M 0.1% 284
2023
Q2 		$75.3M Buy
2,503,458
+29,389
+1% +$1.03M 0.09% 308
2023
Q1 		$89.6M Buy
2,474,069
+53,535
+2% +$2.06M 0.11% 259
2022
Q4 		$86.3M Buy
2,420,534
+50,414
+2% +$1.75M 0.1% 274
2022
Q3 		$80.2M Buy
2,370,120
+32,816
+1% +$1.07M 0.1% 282
2022
Q2 		$67.6M Buy
2,337,304
+17,354
+0.7% +$497K 0.08% 361
2022
Q1 		$75K Buy
2,319,950
+148,522
+7% +$4.55M 0.06% 388
2021
Q4 		$63.3M Buy
2,171,428
+34,357
+2% +$1.04M 0.05% 441
2021
Q3 		$57M Buy
2,137,071
+1,148
+0.1% +$30.8K 0.05% 480
2021
Q2 		$65.8M Buy
2,135,923
+52,205
+3% +$1.6M 0.05% 440
2021
Q1 		$54.6M Sell
2,083,718
-127,442
-6% -$3.56M 0.08% 314
2020
Q4 		$55.6M Buy
2,211,160
+160,161
+8% +$3.45M 0.08% 288
2020
Q3 		$42.7M Buy
2,050,999
+179,045
+10% +$4.06M 0.07% 303
2020
Q2 		$44.5M Buy
1,871,954
+143,690
+8% +$3.17M 0.08% 279
2020
Q1 		$31.1M Buy
1,728,264
+222,444
+15% +$4.67M 0.06% 316
2019
Q4 		$35.7M Buy
1,505,820
+183,442
+14% +$4.46M 0.05% 374
2019
Q3 		$36.3M Buy
1,322,378
+243,377
+23% +$7.21M 0.06% 325
2019
Q2 		$35.7M Buy
1,079,001
+84,846
+9% +$2.91M 0.06% 330
2019
Q1 		$34.8M Buy
994,155
+247,111
+33% +$9.19M 0.06% 340
2018
Q4 		$24.8M Buy
747,044
+178,682
+31% +$7.68M 0.05% 375
2018
Q3 		$28.6M Buy
+568,362
New +$28.1M 0.05% 393
2018
Q2 		– Sell
-78,795
Closed -$3.61M – 2270
2018
Q1 		$3.61M Sell
78,795
-23,943
-23% -$999K 0.01% 845
2017
Q4 		$4.09M Buy
102,738
+15,550
+18% +$614K 0.01% 827
2017
Q3 		$3.49M Sell
87,188
-75,375
-46% -$3.26M 0.01% 838
2017
Q2 		$7.01M Buy
162,563
+2,090
+1% +$74.4K 0.01% 673
2017
Q1 		$5.02M Sell
160,473
-2,260
-1% -$60.6K 0.01% 740
2016
Q4 		$4.11M Sell
162,733
-77,669
-32% -$1.74M 0.01% 783
2016
Q3 		$5.95M Sell
240,402
-50,606
-17% -$1.15M 0.01% 701
2016
Q2 		$5.93M Buy
291,008
+162,608
+127% +$2.88M 0.01% 834
2016
Q1 		$1.96M Buy
+128,400
New +$1.68M ﹤0.01% 955

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group's SUPN Position: Q4 2025 in Review

Macquarie Group sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 2,531,537 shares — an estimated $121M sold.

Macquarie Group first reported a position in SUPN in Q1 2016 and held it in 38 quarters. The position peaked at $121M in Q3 2025. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

  • Macquarie Group reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 2,531,537 Supernus Pharmaceuticals shares in Q4 2025, an estimated $121M.
  • Macquarie Group first reported a position in Supernus Pharmaceuticals in Q1 2016 and held it in 38 quarters.
  • Macquarie Group's Supernus Pharmaceuticals position peaked at $121M in Q3 2025.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.